Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : JDS Uniphase (JDSU) -- Ignore unavailable to you. Want to Upgrade?

To: t2 who wrote (18417)	2/13/2001 3:02:15 PM
From: SJS	Read Replies (2) \| Respond to of 24042

14:45 ET JDS Uniphase (JDSU) 40 23/32 +3/32 (+0.2%): -- Update -- Hearing from sources that the S&P 500 rebalancing of roughly 28 mln JDSU shares will not occur before the close. News is contributing to weakness in the stock.

To: t2 who wrote (18417)	2/13/2001 3:34:31 PM
From: cyberman	Respond to of 24042

But if valuations are what is in question with this post 1999 market - why isn't biotech being scrutinized for its valuations? Some firms like Merrill Lynch are stepping up the scrutiny - Biogen was downgraded by Merrill with a 30-something PE a few weeks back...Making you wonder, why hold any of these biotechs if BGEN is too expensive at that PE Remember also, its unlikely that this sector will be the sector of the year 2 years in a row - money rotation will occur, for instance - once tech comes back, money from all sectors, especially biotech will be moved into tech in my opinion